Atopic Dermatitis in Very Young Patients: Baseline Assessment

Answer the following questions to assess your knowledge of moderate-to-severe pediatric AD.

Markus Boos, MD, PhD

Associate Professor of Pediatrics, Department of Dermatology 
Seattle Children’s - Dermatology
Seattle, Washington

Markus Boos, MD, PhD is an attending pediatric dermatologist at Seattle Children's Hospital and is an Associate Professor in the Department of Pediatrics at the University of Washington School of Medicine. He is also the Associate Program Director for the Dermatology Residency Program at the University of Washington.

Dr. Boos was raised in the suburbs of Detroit and received a BA in Biology and Economics from Kalamazoo College in Kalamazoo, MI. He subsequently joined the Medical Scientist Training Program at the University of Chicago, where he obtained his MD and a PhD degree in Immunology. He completed an internship in Pediatrics at the University of Chicago's Comer Children's Hospital before joining the Hospital of the University of Pennsylvania as a Dermatology resident. There, he served as chief resident during his final year before completing a fellowship in Pediatric Dermatology at the Children's Hospital of Philadelphia.

Lacey L. Kruse, MD

Attending Physician, Dermatology
Associate Professor of Pediatrics-Dermatology
Northwestern University Feinberg School of Medicine
Evanston, Illinois

Lacey Kruse, MD is an Associate Professor of Pediatrics and Dermatology at Northwestern University Feinberg School of Medicine. She has a special interest in and dedication to the medical education of medical students, residents, and fellows. She also serves as program director for the Pediatric Dermatology Fellowship at Ann & Robert H. Lurie Children’s Hospital of Chicago.

Dr. Kruse’s clinical and research interests include pediatric skin cancer, pigmented lesions in children, and atopic dermatitis. She serves as Director for the Lurie Children’s Hospital Pediatric Pigmented Lesion Center of Excellence.
1.
Acquire skills in managing pediatric atopic dermatitis (AD), demonstrating accuracy in assessment, use of evidence-based diagnostic tools, and appropriate referral processes.
2.
Integrate knowledge of efficacy and safety data related to the use of biologics in children ages 6 months to 5 years with moderate-to-severe AD into daily practice.
3.
Apply the latest expert recommendations, including regarding the use of biologics, for treating moderate-to-severe atopic dermatitis (AD) in children aged 6 months to 5 years.